Literature DB >> 14764057

Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells.

A Junaid1, F M Amara.   

Abstract

AIMS: To examine the expression and localization of osteopontin (OPN), a secreted phosphoprotein implicated in the development of tubulointerstitial inflammation in various models of renal disease, in human diabetic kidneys, and to study the regulation of OPN expression in primary cultures of human renal proximal tubular epithelial cells (RPTEC). METHODS AND
RESULTS: Differential gene expression profiling through subtractive hybridization demonstrated increased renal OPN mRNA expression in a patient with diabetic nephropathy. Immunohistochemical staining of normal and diabetic human kidney samples confirmed that OPN was localized to cortical tubular, interstitial and juxtaglomerular compartments. Quantification of OPN immunostaining revealed a marked increase in the percentage of OPN-positive tubular profiles in diabetic kidneys (47 +/- 9% versus 5 +/- 3%, diabetic versus minimal change disease) that correlated strongly with the degree of cortical scarring (r2 = 0.91). Results of Northern hybridization, flow cytometry and Western blotting indicated that glucose up-regulates OPN mRNA and protein expression in primary cultures of human RPTECs. This effect was independent of the osmotic effects of glucose and independent of insulin. Finally, glucose-stimulated OPN expression was inhibited by LY294002, an inhibitor of phosphatidylinositol 3-kinase activity, in a dose-dependent manner.
CONCLUSIONS: OPN is expressed in human diabetic kidneys and regulation of OPN expression is via a glucose-mediated, phosphatidylinositol 3-kinase-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764057     DOI: 10.1111/j.1365-2559.2004.01771.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  15 in total

1.  Atorvastatin inhibits hyperglycemia-induced expression of osteopontin in the diabetic rat kidney via the p38 MAPK pathway.

Authors:  Li Zuo; Yong Du; Man Lu; Junling Gao; Ruolei Hu; Sumei Zhang; Yi Wang; Huaqing Zhu; Qing Zhou; Wei Wei; Yuan Wang
Journal:  Mol Biol Rep       Date:  2014-01-23       Impact factor: 2.316

Review 2.  Gene expression in diabetic nephropathy.

Authors:  Daniela Hohenadel; Fokko J van der Woude
Journal:  Curr Diab Rep       Date:  2004-12       Impact factor: 4.810

Review 3.  Investigating Polyphenol Nanoformulations for Therapeutic Targets against Diabetes Mellitus.

Authors:  Fahadul Islam; Jannatul Fardous Khadija; Md Rezaul Islam; Sheikh Shohag; Saikat Mitra; Saad Alghamdi; Ahmad O Babalghith; Abdulrahman Theyab; Mohammad Tauhidur Rahman; Aklima Akter; Abdullah Al Mamun; Fahad A Alhumaydhi; Talha Bin Emran
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-21       Impact factor: 2.650

4.  Matrix Metalloproteinase 20 Co-expression With Dentin Sialophosphoprotein in Human and Monkey Kidneys.

Authors:  Kalu U E Ogbureke; Komal Koli; Geetu Saxena
Journal:  J Histochem Cytochem       Date:  2016-10       Impact factor: 2.479

5.  Osteopontin and other regulators of angiogenesis and fibrogenesis in the vitreous from patients with proliferative vitreoretinal disorders.

Authors:  Ahmed M Abu El-Asrar; Mohd Imtiaz Nawaz; Dustan Kangave; Mohammed Mairaj Siddiquei; Karel Geboes
Journal:  Mediators Inflamm       Date:  2012-09-29       Impact factor: 4.711

6.  Expression of high-mobility groups box-1/receptor for advanced glycation end products/osteopontin/early growth response-1 pathway in proliferative vitreoretinal epiretinal membranes.

Authors:  Ahmed M Abu El-Asrar; Luc Missotten; Karel Geboes
Journal:  Mol Vis       Date:  2011-02-17       Impact factor: 2.367

7.  Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus.

Authors:  Xiaoxiang Yan; Motoaki Sano; Lin Lu; Wei Wang; Qi Zhang; Ruiyan Zhang; Lingjie Wang; Qiujing Chen; Keiichi Fukuda; Weifeng Shen
Journal:  Cardiovasc Diabetol       Date:  2010-10-29       Impact factor: 9.951

8.  Osteopontin plays a critical role in interstitial fibrosis but not glomerular sclerosis in diabetic nephropathy.

Authors:  Tomoaki Nagao; Takafumi Okura; Jun Irita; Masanori Jotoku; Daijiro Enomoto; Veena Rasika Desilva; Ken-Ichi Miyoshi; Mie Kurata; Yutaka Matsui; Toshimitsu Uede; Jitsuo Higaki
Journal:  Nephron Extra       Date:  2012-03-29

Review 9.  Epigallocatechin Gallate: A Review of Its Beneficial Properties to Prevent Metabolic Syndrome.

Authors:  Samuel Legeay; Marion Rodier; Laetitia Fillon; Sébastien Faure; Nicolas Clere
Journal:  Nutrients       Date:  2015-07-07       Impact factor: 5.717

Review 10.  Regulation of Monocytes/Macrophages by the Renin-Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study.

Authors:  Claudine Moratal; Audrey Laurain; Mourad Naïmi; Thibault Florin; Vincent Esnault; Jaap G Neels; Nicolas Chevalier; Giulia Chinetti; Guillaume Favre
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.